Posted by Michael Wonder on 09 Jun 2026
Sarclisa subcutaneous approved in the EU as the first anticancer treatment administered via an on-body injector
8 June 2026 - The European Commission has approved Sarclisa (isatuximab) subcutaneous in combination with standard of care regimens for the treatment of patients with multiple myeloma across all existing indications for Sarclisa intravenous formulation.
Sarclisa is the first anticancer therapy in the EU to be administered through an on-body injector and manual subcutaneous administration and can provide the flexibility of administration at patients’ homes and in the outpatient setting.
